{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"groups":[{"description":"Patients who have relapsed/progressed within 180 days post-transplant (Cohort 1), beyond day 180 post-transplant (Cohort 2), or within 6 months but were not started within 3 months of relapse, receive lenalidomide PO QD on days 1-28 (patients with CLL/SLL/PLL) or days 1-21 (patients with NHL). Patients in Cohorts 1 and 2 also receive rituximab IV on days 1, 8, 15, and 22 of course 1 and then every two months for courses 3, 5, 7, 9, and 11.\n\nlenalidomide: Given PO\n\nrituximab: Given IV\n\npharmacological study: Correlative studies\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Arm I (Lenalidomide, Rituximab)"},{"description":"Patients who have relapsed/progressed at any time point post-transplant and who have contraindications, prior severe hypersensitivity reaction to rituximab infusion, to receive rituximab or have CD20 negative disease (Cohort 3) receive lenalidomide as in Arm I.\n\nlenalidomide: Given PO\n\npharmacological study: Correlative studies\n\nlaboratory biomarker analysis: Correlative studies","id":"OG001","title":"Arm II (Lenalidomide)"}],"paramType":"NUMBER","populationDescription":"No participants enrolled in the second arm. Not enough participants in first arm to make meaningful comparisons to historic controls.","reportingStatus":"POSTED","timeFrame":"Assessed up to 30 days after completion of study treatment","title":"Comparison of Incidences of Adverse Events Between the First, Second, and Third Cohorts","type":"SECONDARY","unitOfMeasure":"Number of adverse events"}